Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Does prophylactic N acetylcysteine decrease the incidence of contrast nephropathy in patients undergoing endovascular abdominal aortic aneurysm (AAA) repair?
ISRCTN ISRCTN69248640
ClinicalTrials.gov identifier
Public title Does prophylactic N acetylcysteine decrease the incidence of contrast nephropathy in patients undergoing endovascular abdominal aortic aneurysm (AAA) repair?
Scientific title
Acronym N/A
Serial number at source N0544139644
Study hypothesis Is peri-operative oral N acetylcysteine nephroprotective in patients undergoing endovascular abdominal aortic aneurysm repair?
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Surgery: Abdominal aortic aneurysm (AAA) repair
Participants - inclusion criteria Not provided at time of registration
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 16/12/2003
Anticipated end date 15/12/2006
Status of trial Completed
Patient information material
Target number of participants 20
Interventions Participation offered to all patients undergoing endovascular abdominal aortic aneurysm repair in the Cambridge Vascular Unit, Addenbrooke's Hospital. Consenting patients will be randomised to receive either intra venous saline hydration (current practice) or intravenous saline hydration and oral N acetyl-cysteine (600 mg twice a day (bd) orally (PO) on the day before the procedure; and 600 mg bd PO on the day of the procedure, one dose before, and one dose after the procedure). Evidence of renal injury will be monitored post-procedure by assay of serum creatinine levels, and also by measuring urinary low molecular weight proteins such as N acetyl beta glucosaminidase (NAG) a subclinical marker of renal injury, and albumin and creatinine.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Cambridge Consortium - Addenbrooke's (UK)
Trial website
Publications 2006 results on http://www.ncbi.nlm.nih.gov/pubmed/17042662
Contact name Mr  J  Boyle
  Address Cambridge Vascular Unit
Dept. of General Surgery
Box 201
Addenbrooke's Hospital
  City/town Cambridge
  Zip/Postcode CB2 2QQ
  Country United Kingdom
  Tel +44 (0)1223 217246
  Fax +44 (0)1223 216015
  Email jonathan.boyle@addenbrookes.nhs.uk
Sponsor Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
  Address The Department of Health,
Richmond House,
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2004
Last edited 18/02/2008
Date ISRCTN assigned 30/09/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central